After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...

Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year to $4.71 billion. Its non-GAAP profit of $2.90 per share was 4.5% above ...

BD’s new MiniDraw diagnostic devices could let pharmacists—and, one day, maybe patients—manage blood testing needs and monitor health conditions. BD received its FDA authorizations for two blood draw ...

BD named Vitor Roque as chief financial officer Thursday, ending the medtech company’s seven-month search for a permanent ...

BD (NYSE:BDX) today announced the appointment of a new CFO alongside Street-beating second-quarter financial results.

After nearly a century spent building out its portfolio of insulin pens and syringes, BD is finally ready to let its diabetes care business leave the nest. While reporting financial results for the ...

Becton Dickinson & Co. is set to make additional investments in its U.S. manufacturing network to add capacity for critical medical devices. “BD has a longstanding history as a leading U.S.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...